Novel therapeutic strategies in development for prostate cancer

Bibliography

• Attard G, Yap TA, Reid AH, et al. Activity, toxicity, and effect on steroid precursor levels of abiraterone (A), an oral irreversible inhibitor of CYP17 (17α hydroxylase/17,20 lyase), in castrate men with castration refractory prostate cancer (CRPC). Prostate Cancer Symposium, Orlando, Florida; 2007 (Abstract)
   Google Scholar
• Ryan CJ, Rosenberg J, Lin A, Valiente J, Kim J, Small EJ. Phase I evaluation of abiraterone acetate (CB7630), a 17 alpha hydroxylase C17,20-Lyase inhibitor in androgen-independent prostate cancer (AiPC). J Clin Oncol, ASCO Annual Meeting Proceedings 2007;25(18S):5064 (Abstract)
   Google Scholar
• George DJ, Halabi S, Shepard TF, et al. Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on cancer and leukemia group B 9480. Clin Cancer Res 2001;7(7):1932-6
   PubMed Web of Science ®Google Scholar
• Bok RA, Halabi S, Fei DT, et al. Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: a cancer and leukemia group B study. Cancer Res 2001;61(6):2533-6
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350(23):2335-42
   PubMed Web of Science ®Google Scholar
• Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355(24):2542-50
   PubMed Web of Science ®Google Scholar
• Miller KD, Chap LI, Holmes FA, et al. Randomized Phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005;23(4):792-9
   PubMed Web of Science ®Google Scholar
• Reese DM, Fratesi P, Corry M, Novotny W, Holmgren E, Small EJ. A Phase II trial of humanized anti-vascular endothelial growth factor antibody for the treatment of androgen-independent prostate cancer. Prostate J 2001;3(2):65-70
   Google Scholar
• Picus J, Halabi S, Rini B, et al. The use of bevacizumab with docetaxel and estramustine in hormone refractory prostate cancer: initial results of CALGB 90006. Proc Am Soc Clin Oncol 2003;22:1578 (Abstract)
   Google Scholar
• Ning YM, Arlen P, Gulley JL, et al. A Phase II trial of thalidomide, bevacizumab, and coetaxel in patients with metastatic androgen-independent prostate cancer. J Clin Oncol, ASCO Annual Meeting Proceedings 2007;25(18S):5114 (Abstract)
   Google Scholar
• Wood DP Jr, Beaman A, Banarjee M, Powell I, Pontes E, Cher ML. Effect of neoadjuvant androgen deprivation on circulating prostate cells in the bone marrow of men undergoing radical prostatectomy. Clin Cancer Res 1998;4(9):2119-23
   PubMed Web of Science ®Google Scholar
• Chi KN, Chin E, Winquist SL, et al. Multicenter Phase II study of combined docetaxel and neoadjuvant hormone therapy (NHT) prior to prostatectomy for patients with high risk localized prostate cancer: pathologic outcomes and 3-year follow-up analyses. Prostate Cancer Symposium, Orlando, Florida; 2007 (Abstract)
   Google Scholar
• Febbo PG, Richie JP, George DJ, et al. Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer. Clin Cancer Res 2005;11(14):5233-40
   PubMed Web of Science ®Google Scholar
• O'brien CA, Garzotto M, Higano CS, et al. Predictors of early relapse in high risk prostate cancer patients treated with neoadjuvant mitoxantrone and docetaxel. J Clin Oncol, ASCO Annual Meeting Proceedings 2005;23(16S):4640 (Abstract)
   Google Scholar
• Garzotto M, Higano CS, LOWE BA, et al. Neoadjuvant weekly docetaxel and mitoxantrone in patients with high risk localized prostate cancer: a Phase I trial. Proc Am Soc Clin Oncol 2002;21:2434 (Abstract)
   Google Scholar
• Friedman JD, Vaishampayan U, Wood D, et al. Neoadjuvant docetaxel and capecitabine in patients with high-risk prostate cancer: final results of a Phase II trial. J Clin Oncol, ASCO Annual Meeting Proceedings 2007;25(18S):5147 (Abstract)
   PubMed Web of Science ®Google Scholar
• Eastham JA, Kelly WK, Grossfeld GD, Small EJ. Cancer and leukemia group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease. Urology 2003;62(Suppl 1):55-62
   PubMedGoogle Scholar
• Kibel AS, Rosenbaum E, Kattan MW, et al. Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study. J Urol 2007;5:1777-81
   Google Scholar
• Patel AR, Sandler HM, Pienta KJ, et al. Radiation Therapy Oncology Group 0521: a Phase III randomized trial of androgen suppression and radiation therapy versus androgen suppression and radiation therapy followed by chemotherapy with docetaxel/prednisone for localized, high-risk prostate cancer. Clin Genitourin Cancer 2005;4(3):212-14
   PubMedGoogle Scholar
• Fizazi K, Gravis G, Culine S, et al. The GETUG 12 trial, a Phase III randomized trial of docetaxel-estramustine in high-risk localized prostate cancer: clinical design and current status. Prostate Cancer Symposium, Orlando, Florida; 2007 (Abstract)
   Google Scholar
• Sternberg CN. Satraplatin in the treatment of hormone-refractory prostate cancer. BJU Int 2005;96(7):990-4
   PubMed Web of Science ®Google Scholar
• Sternberg CN, Whelan P, Hetherington J, et al. Phase III trial of satraplatin, an oral platinum plus prednisone vs. prednisone alone in patients with hormone-refractory prostate cancer. Oncology 2005;68(1):2-9
   PubMed Web of Science ®Google Scholar
• Latif T, Wood L, Connell C, et al. Phase II study of oral bis (aceto) ammine dichloro (cyclohexamine) platinum (IV) (JM-216, BMS-182751) given daily × 5 in hormone refractory prostate cancer. Invest New Drugs 2005;23(1):79-84
   PubMed Web of Science ®Google Scholar
• Petrylak DP, Sartor O, Witjes F, et al. A Phase III, randomized, double-blind trial of satraplatin and prednisone vs. placebo and prednisone for patients with hormone refractory prostate cancer. Prostate Cancer Symposium, San Francisco, California; 2006 (Abstract)
   Google Scholar
• Sternberg CN, Petrylak D, Witjes F, et al. Satraplatin demonstrates significant clinical benefits fo rthe treatment of patients with HRPC: results of a randomized Phase III trial. J Clin Oncol, ASCO Annual Meeting Proceedings. 2007;25(18S):5019 (Abstract)
   PubMed Web of Science ®Google Scholar
• Hussain M, Tangen CN, Lara PN Jr, et al. Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111. J Clin Oncol 2005;23(34):8724-9
   PubMed Web of Science ®Google Scholar
• Galsky MD, Small EJ, Oh WK, et al. Multi-institutional randomized Phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer. J Clin Oncol 2005;23(7):1439-46
   PubMed Web of Science ®Google Scholar
• Smaletz O, Galsky M, Scher HI, et al. Pilot study of epothilone B analog (BMS-247550) and estramustine phosphate in patients with progressive metastatic prostate cancer following castration. Ann Oncol 2003;14(10):1518-24
   PubMed Web of Science ®Google Scholar
• Rosenberg JE, Weinberg VK, Beer T, et al. NCI 7347: Phase I/II trial of epothilone analog BMS-247550 (ixabepilone), mitoxantrone, and prednisone in hormone refractory prostate cancer patients previously treated with chemotherapy. Prostate Cancer Symposium, Orlando, Florida; 2007 (Abstract)
   Google Scholar
• Sanda MG, Ayygari SR, Jaffee EM, et al. Demonstration of a rational strategy for human prostate cancer gene therapy. J Urol 1994;151(3):622-8
   PubMed Web of Science ®Google Scholar
• Carlsson B, Totterman TH, Essand M. Generation of cytotoxic T lymphocytes specific for the prostate and breast tissue antigen TARP. Prostate Cancer Symposium, Orlando, Florida; 2007 (Abstract)
   Google Scholar
• Small EJ, Schellhammer PF, Higano CS, et al. Placebo-controlled Phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006;24(19):3089-94
   PubMed Web of Science ®Google Scholar
• Simons JW, Sacks N. Granulocyte-macrophage colony-stimulating factor-transduced allogeneic cancer cellular immunotherapy: the GVAX vaccine for prostate cancer. Urol Oncol 2006;24(5):419-24
   PubMed Web of Science ®Google Scholar
• Warren TL, Weiner GJ. Uses of granulocyte-macrophage colony-stimulating factor in vaccine development. Curr Opin Hematol 2000;7(3):168-73
   PubMed Web of Science ®Google Scholar
• Halabi S, Small EJ, Kantoff PW, et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 2003;21(7):1232-7
   PubMed Web of Science ®Google Scholar
• Simons JW, Small E, Nelson W, et al. Phase II trials of a GM-CSF gene-transduced prostate cancer cell line vaccine (GVAX) demonstrate anti-tumor activity. Proc Am Soc Clin Oncol 2001;20:1073 (Abstract)
   Google Scholar
• Simons J, Nelson W, Nemunaitis J, et al. Phase II trials of a GM-CSF gene-transduced prostate cancer cell line vaccine (GVAX) in hormone refractory prostate cancer. Proc Am Soc Clin Oncol 2002;21:729 (Abstract)
   Google Scholar
• Small EJ, Higano C, Smith D, et al. A Phase II study of an allogeneic GM-CSF gene-transduced prostate cancer cell line vaccine in patients with metastatic hormone-refractory prostate cancer. Prostate Cancer Symposium, Orlando, Florida; 2005 (Abstract)
   Google Scholar
• Cell Genesys: Cell genesys completes patient recruitment for first Phase III clinical trial of GVAX immunotherapy for prostate cancer. 2007 [cited 2007 August 8]; Available from: http://phx.corporate-ir.net/ phoenix.zhtml? c=98399&p=irol-newsArticle&ID =1024159&highlight=
   Google Scholar
• Small EJ, Tchekmedyian NS, Rini BI, Fong L, Israel L, Allison JP. A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin Cancer Res 2007;13(6):1810-15
   PubMed Web of Science ®Google Scholar
• Fong L, Kavanaugh B, Hou Y, et al. Combination immunotherapy with GM-CSF and CTLA-4 blockade for hormone refractory prostate cancer: balancing the expansion of activated effector and regulatory T cells. J Clin Oncol, ASCO Annual Meeting. Proceedings 2007;25(18S):3001 (Abstract)
   Google Scholar
• Gerritsen W, Van Den Eertwegh AJ, De Gruijl TD, et al. A dose-escalation trial of GM-CSF-gene transduced allogeneic prostate cancer cellular immunotherapy in combination with fully human anti-CTL4 antibody (MDX-010, ipilimumab) in patients with metastatic hormone-refractory prostate cancer (MHRPC). Prostate Cancer Symposium, Orlando, Florida; 2007 (Abstract)
   Google Scholar
• Beer TM, Ryan CW, Venner PM, et al. Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT investigators. J Clin Oncol 2007;25(6):669-74
   PubMed Web of Science ®Google Scholar
• Beer TM, Venner PM, Ryan CW, et al. High dose calcitriol may reduce thrombosis in cancer patients. Br J Haematol 2006;135(3):392-4
   PubMed Web of Science ®Google Scholar
• Venner PM, Ryan C, Petrylak DP, et al. Reduced thromboembolic events with DN-101 (high-dose calcitriol) treatment of androgen-independent prostate cancer: hypothesis for a new class of anticoagulants. J Clin Oncol, ASCO Annual Meeting Proceedings 2006;24(18S):4505 (Abstract)
   Google Scholar
• Guise TA, Mohammed KS. Endothelins in bone cancer metastases. Cancer Treat Res 2004;118:197-212
   PubMedGoogle Scholar
• Nelson JB, Chin JL, Love W, et al. Results of a Phase III randomized controlled trial of the safety and efficacy of atrasentan in men with nonmetastatic hormone-refractory prostate cancer (HRPC). Prostate Cancer Symposium, Orlando, Florida; 2007 (Abstract)
   Google Scholar
• Nelson JB, Chin JL, Love W, et al. Results of a Phase III randomized controlled trial of the safety and efficacy of atrasentan in men with nonmetastatic hormone-refractory prostate cancer (HRPC). J Clin Oncol, ASCO Annual Meeting Proceedings 2007;25(18S):5018 (Abstract)
   Google Scholar
• Wilhelm S, Chien DS. BAY 43-9006: preclinical data. Curr Pharm Des 2002;8(25):2255-7
   PubMed Web of Science ®Google Scholar
• Dahut WL, Scripture CD, Posadas EM, et al. Bony metastatic disease responses to sorafenib (BAY 43-9006) independent of PSA in patients with metastatic androgen independent prostate cancer. J Clin Oncol, ASCO Annual Meeting Proceedings 2006;24(18S):4506 (Abstract)
   Google Scholar
• Steinbild S, Mross K, Morant D, et al. Phase II study of sorafenib (BAY 43-9006) in hormone-refractory patients with prostate cancer: a study of the central European society for anticancer drug research–EWIV (CESAR). J Clin Oncol, ASCO Annual Meeting Proceedings 2006;24(18S):3094 (Abstract)
   Google Scholar
• Gerritsen W, Van Den Eertwegh AJ, De Gruijl TD, et al. Biochemical and immunologic correlates of clinical response in a combination trial of the GM-CSF-gene transduced allogeneic prostate cancer immunotherapy and ipilimumab in patients with metastatic hormone-refractory prostate cancer. J Clin Oncol, ASCO Annual Meeting Proceedings 2007;25(18S):5120 (Abstract)
   Google Scholar